Zevra Therapeutics, Inc. Announces CFO Transition
Zevra Therapeutics (NasdaqGS: ZVRA) announced that Chief Financial Officer and Treasurer R. LaDuane Clifton will step down effective December 31, 2025 to pursue other professional opportunities. Clifton has served since 2015, and company leadership said he helped guide Zevra from development stage to a commercial-stage rare disease company and left a strong financial foundation.
The company has initiated a search for a new chief financial officer. No replacement has been named and no financial metrics or guidance changes were disclosed.
Zevra Therapeutics (NasdaqGS: ZVRA) ha annunciato che il direttore finanziario e tesoriere R. LaDuane Clifton lascerà l'incarico con effetto 31 dicembre 2025 per perseguire altre opportunità professionali. Clifton è stato in carica dal 2015, e la dirigenza ha affermato che ha contribuito a guidare Zevra dallo stadio di sviluppo a una azienda di produzione commerciale nel settore delle malattie rare e ha lasciato una solida base finanziaria.
L'azienda ha avviato una ricerca per un nuovo direttore finanziario. Nessuna sostituzione è stata annunciata e non sono stati divulgati cambiamenti nelle metriche finanziarie o nelle previsioni.
Zevra Therapeutics (NasdaqGS: ZVRA) anunció que el Director Financiero y Tesorero R. LaDuane Clifton dejará el cargo con efecto a partir del 31 de diciembre de 2025 para buscar otras oportunidades profesionales. Clifton ha estado en el cargo desde 2015, y la dirección de la empresa dijo que ayudó a guiar a Zevra desde la etapa de desarrollo hasta convertirse en una empresa de enfermedades raras en etapa comercial, dejando una base financiera sólida.
La compañía ha iniciado una búsqueda de un nuevo director financiero. No se ha designado un reemplazo y no se divulgaron cambios en métricas financieras o guías.
Zevra Therapeutics (NasdaqGS: ZVRA)는 최고재무책임자 겸 재무담당자 R. LaDuane Clifton이 2025년 12월 31일부로 사임하고 다른 전문적 기회를 추구할 것이라고 발표했습니다. Clifton은 2015년부터 재직해 왔으며, 회사 경영진은 그가 Zevra를 개발 단계에서 상용 단계의 희귀질환 기업으로 이끌고 탄탄한 재무 기반을 마련했다고 말했습니다.
회사는 새로운 최고재무책임자를 찾기 시작했습니다. 아직 교체 인물이 지명되지 않았으며 재무 지표나 가이던스의 변화는 공개되지 않았습니다.
Zevra Therapeutics (NasdaqGS: ZVRA) a annoncé que le directeur financier et trésorier R. LaDuane Clifton quittera ses fonctions à compter du 31 décembre 2025 pour poursuivre d'autres opportunités professionnelles. Clifton est en poste depuis 2015, et la direction de l'entreprise a déclaré qu'il a aidé Zevra à passer du stade de développement à une société de maladies rares en stade commercial et a laissé une base financière solide.
L'entreprise a lancé une recherche pour un nouveau directeur financier. Aucune nomination de remplacement n'a été annoncée et aucun indicateur financier ni aucune prévision n'a été dévoilé.
Zevra Therapeutics (NasdaqGS: ZVRA) gab bekannt, dass der Chief Financial Officer und Treasurer R. LaDuane Clifton mit Wirkung zum 31. Dezember 2025 zurücktreten wird, um andere berufliche Möglichkeiten zu verfolgen. Clifton ist seit 2015 im Amt, und die Führung des Unternehmens sagte, er habe Zevra vom Entwicklungsstadium zu einem kommerzialisierten Unternehmen im Bereich seltener Krankheiten geführt und eine starke finanzielle Grundlage geschaffen.
Das Unternehmen hat eine Suche eingeleitet nach einem neuen Chief Financial Officer. Es wurde noch kein Ersatz benannt und keine finanziellen Kennzahlen oder Leitplankenänderungen wurden veröffentlicht.
Zevra Therapeutics (NasdaqGS: ZVRA) أعلنت أن المدير المالي والأمين المالي R. LaDuane Clifton سيتنحى عن منصبه اعتباراً من 31 ديسمبر 2025 لمتابعة فرص مهنية أخرى. خدم Clifton منذ 2015، وقالت قيادة الشركة إنه ساهم في قيادة Zevra من مرحلة التطوير إلى شركة رعاية صحية نادرة في مرحلة تجارية وترك قاعدة مالية قوية.
أعلنت الشركة عن بدء البحث عن مدير مالي جديد. لم يتم تعيين بديل بعد ولم يتم الكشف عن أي تغييرات في المعايير المالية أو التوجيه.
- CFO tenure since 2015 established continuity
- Management says CFO left a strong financial foundation
- CFO R. LaDuane Clifton to step down Dec 31, 2025
- Ongoing CFO search creates near-term leadership uncertainty
CELEBRATION, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financial Officer and Treasurer, R. LaDuane Clifton, will be stepping down from his position with the Company, effective December 31, 2025, in order to pursue other professional opportunities.
"Since joining the Company in 2015, LaDuane has provided steady leadership and invaluable guidance, leaving a lasting impact on the Company," said Neil F. McFarlane, Zevra’s Chief Executive Officer and President. "He has played a pivotal role in our journey as we navigated our transition from development stage into a commercial-stage company focused on rare disease and leaves Zevra with a strong financial foundation to support the next phase of our growth. On a personal note, I want to thank LaDuane for his unwavering dedication and partnership over the years."
"It has been a great honor to be a part of the Zevra journey," said Mr. Clifton. "As I move on to my next endeavors, I am confident that the corporate foundation we have built will sustain and propel the Company into a bright future ahead."
The Company has initiated a search to identify its next chief financial officer.
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. is a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Expanded access programs are made available by Zevra Therapeutics, Inc. and its affiliates and are subject to the Company's Expanded Access Program (EAP) policy, as published on its website. Participation in these programs is subject to the laws and regulations of each jurisdiction under which each respective program is operated. Eligibility for participation in any such program is at the treating physician's discretion.
Cautionary Note Concerning Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding executive transitions and the timing thereof. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025, filed on November 5, 2025, as well as Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
Zevra Contact
Nichol Ochsner
+1 (732) 754-2545
nochsner@zevra.com
FAQ
When will Zevra Therapeutics (ZVRA) CFO R. LaDuane Clifton leave the company?
Has Zevra (ZVRA) named a replacement for CFO R. LaDuane Clifton?
How long did R. LaDuane Clifton serve as Zevra (ZVRA) CFO?
Does the Zevra (ZVRA) announcement include changes to earnings guidance or financial metrics?
What reason did Zevra (ZVRA) give for CFO R. LaDuane Clifton's departure?
